$90.9 Million is the total value of Summit Rock Advisors, LP's 5 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ACWI | Buy | ISHARES TRmsci acwi etf | $32,774,000 | +4926.7% | 441,341 | +4713.4% | 36.06% | +7773.6% |
| IEMG | Buy | ISHARES INCcore msci emkt | $21,928,000 | +17.0% | 423,477 | +18.7% | 24.13% | +83.2% |
| HYG | Buy | ISHARES TRiboxx hi yd etf | $14,360,000 | +497.6% | 166,123 | +488.3% | 15.80% | +835.5% |
| IUSV | Sell | ISHARES TRcore s&p us vlu | $11,942,000 | -81.0% | 211,818 | -81.9% | 13.14% | -70.2% |
| EFV | Sell | ISHARES TReafe value etf | $9,880,000 | -82.9% | 190,295 | -83.1% | 10.87% | -73.2% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-10-25
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ISHARES TR | 29 | Q3 2020 | 90.6% |
| ISHARES TR | 26 | Q4 2020 | 51.7% |
| ISHARES INC | 11 | Q1 2020 | 64.0% |
| ISHARES TR | 11 | Q4 2021 | 47.6% |
| ISHARES TR | 9 | Q2 2015 | 34.5% |
| PHATHOM PHARMACEUTICALS INC | 9 | Q2 2022 | 1.1% |
| ISHARES TR RUS 2000 VAL ETF | 7 | Q4 2022 | 47.0% |
| SELECT SECTOR SPDR TR ENERGY | 6 | Q3 2023 | 67.4% |
| VANGUARD INTL EQUITY INDEX F | 5 | Q3 2022 | 45.3% |
| VANGUARD INDEX FDS | 4 | Q4 2021 | 36.4% |
View Summit Rock Advisors, LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-01-26 |
| 13F-HR | 2023-10-24 |
| 13F-HR | 2023-07-21 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-01-12 |
| 13F-HR | 2022-11-02 |
| 13F-HR | 2022-08-01 |
| 13F-HR | 2022-05-06 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-10-26 |
View Summit Rock Advisors, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.